menu

A Multidisciplinary Approach to Managing Potassium Levels in Patients with Heart Failure When Optimizing RAASi Therapy in Comple

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A Multidisciplinary Approach to Managing Potassium Levels in Patients with Heart Failure When Optimizing RAASi Therapy in Complex Cases

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Heart failure and chronic kidney disease can go hand in hand in your patients, and when they do, there are often added comorbidities such as diabetes. If your patients on RAASi therapy develop hyperkalemia, what should you do? Join Drs. Patrick Rossignol and Antoni Bayés-Genís as they consult on a patient with heart failure who has multiple comorbidities and discuss the impact of hyperkalemia in these complex patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Antoni Bayés-Genís, MD, PhD, FESC, FHFA
    Director de l'Institut del Cor
    Hospital Universitari Germans Trias i Pujol
    Catedràtic, Departament de Medicina, Universitat Autònoma de Barcelona
    Barcelona, Spain

    Consulting Fees: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Novartis, Roche Diagnostics

    Faculty:
    Patrick Rossignol, MD, PhD
    Head of Medical Specialties Service (Nephrology–Haemodialysis)
    Princess Grace Hospital
    Medical Director, Monaco Private Haemodialysis Centre
    Monaco, France

    Consulting Fees: Ablative Solutions, AstraZeneca, Bayer, Boehringer-Ingelheim, CinCor, Corvidia, CVRx, Fresenius, G3P, Grunenthal, Idorsia, KBP, Novartis, Novo Nordisk, Relypsa, Sanofi, Sequana Medical, Servier, Stealth Peptides, Vifor Fresenius Medical Care Renal Pharma
    Contracted Research: CSL Vifor
    Ownership Interest: CardioRenal, G3P

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Howard Green has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the clinical impact of hyperkalemia in patients with heart failure with reduced ejection fraction (HFrEF) complicated by comorbid conditions
    • Evaluate the clinical trial data concerning the use of potassium binders in patients with HFrEF and diabetes
    • Develop strategies for using potassium binders to manage heart failure short or long term to improve patient outcomes
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, primary care physicians, nephrologists, and all other HCPs involved in the identification and treatment of patients with heart failure.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Heart failure and chronic kidney disease can go hand in hand in your patients, and when they do, there are often added comorbidities such as diabetes. If your patients on RAASi therapy develop hyperkalemia, what should you do? Join Drs. Patrick Rossignol and Antoni Bayés-Genís as they consult on a patient with heart failure who has multiple comorbidities and discuss the impact of hyperkalemia in these complex patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Antoni Bayés-Genís, MD, PhD, FESC, FHFA
    Director de l'Institut del Cor
    Hospital Universitari Germans Trias i Pujol
    Catedràtic, Departament de Medicina, Universitat Autònoma de Barcelona
    Barcelona, Spain

    Consulting Fees: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Novartis, Roche Diagnostics

    Faculty:
    Patrick Rossignol, MD, PhD
    Head of Medical Specialties Service (Nephrology–Haemodialysis)
    Princess Grace Hospital
    Medical Director, Monaco Private Haemodialysis Centre
    Monaco, France

    Consulting Fees: Ablative Solutions, AstraZeneca, Bayer, Boehringer-Ingelheim, CinCor, Corvidia, CVRx, Fresenius, G3P, Grunenthal, Idorsia, KBP, Novartis, Novo Nordisk, Relypsa, Sanofi, Sequana Medical, Servier, Stealth Peptides, Vifor Fresenius Medical Care Renal Pharma
    Contracted Research: CSL Vifor
    Ownership Interest: CardioRenal, G3P

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Howard Green has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the clinical impact of hyperkalemia in patients with heart failure with reduced ejection fraction (HFrEF) complicated by comorbid conditions
    • Evaluate the clinical trial data concerning the use of potassium binders in patients with HFrEF and diabetes
    • Develop strategies for using potassium binders to manage heart failure short or long term to improve patient outcomes
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, primary care physicians, nephrologists, and all other HCPs involved in the identification and treatment of patients with heart failure.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule12 Jul 2024